Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance
- 15 May 1989
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 43 (5) , 880-885
- https://doi.org/10.1002/ijc.2910430524
Abstract
To see whether a tumor cell population may contain cells resistant to lymphokine‐activated killer (LAK) lymphocytes, cells from a LAK‐sensitive melanoma line (Me 665/2) were co‐cultured with LAKs. Three sublines were obtained after 1, 2 or 3 immunoselection cycles. Immunoselected (IS) sublines show reduced proliferation, decreased reactivity to the monoclonal antibody (MAb) R24 and appeared morphologically more differentiated in comparison with the parental Me 665/2 line. A progressively reduced sensitivity to LAKs was observed in IS sublines with a more than 8‐fold reduction in LAK susceptibility. A reduced complement (C)‐mediated lysis was also observed in IS sublines. Since we have previously shown that LAK sensitivity of melanoma cells may be associated with Doxorubicin (Dx) resistance, the sensitivity to Dx was tested in these lines. An augmented sensitivity to Dx was noted in IS sublines as compared with Me 665/2. The differences in LAK susceptibility between the IS sublines and the parental Me 665/2 line remained stable for 2 weeks but declined and disappeared thereafter. These results indicate that (1) a LAK‐sensitive tumor line may contain a subpopulation of cells which are significantly less lysed by LAKs; (2) a correlation between LAK sensitivity and susceptibility to C‐mediated lysis is also present; and (3) increased sensitivity to Dx is evident in the IS sublines.This publication has 20 references indexed in Scilit:
- Perforin — a primary pr auxiliary lytic mechanism?Immunology Today, 1988
- Differential lysis of melanoma clones by autologous recombinant interleukin 2‐activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx)International Journal of Cancer, 1988
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin‐2 activated killer cells and by activated monocytesInternational Journal of Cancer, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon γInternational Journal of Cancer, 1986
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983
- Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.The Journal of Experimental Medicine, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982